#1 Clinical Trials Search in Europe

(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID

Clinical trials are investigating “(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID” in patients with coronary artery disease. The study is designed to evaluate whether it can affect recovery after on-pump coronary artery bypass grafting surgery, with a focus on hospital stay after surgery.

Table of Contents

Trial overview

One clinical trial is listed for “(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID”. The study is an interventional trial, which means researchers give a treatment and then measure the results.[1]

The trial is focused on people with coronary artery disease who are having on-pump coronary artery bypass grafting surgery.[1]

Study design and treatment groups

This study is a Phase 3 trial, which is a later-stage study in a larger group of patients.[1]

It is described as randomized, double-blind, and placebo-controlled.[1]

Randomized means patients are assigned by chance to a study group. Double-blind means neither the patient nor the study team knows which treatment is given. Placebo-controlled means one group receives a comparison treatment that does not contain the active study drug.[1]

  • One group receives EA-230 given by intravenous administration, which means through a vein.[1]
  • The other group receives NaCl 29 mg/ml in water for injection, which is the placebo used for comparison.[1]

Who can participate

The source data says the trial is for people with coronary artery disease who are undergoing on-pump coronary artery bypass grafting surgery.[1]

No more detailed inclusion or exclusion rules are provided in the trial data, so the full eligibility list is not available here.[1]

What is being measured

The main goal of the trial is to assess the effect of the study treatment on postoperative hospital length of stay, which means how long a patient stays in the hospital after surgery.[1]

The primary outcome is the median postoperative duration from the first incision until the patient is eligible to be discharged from the hospital.[1]

Median means the middle value in a group of results. The study compares this outcome between the treatment groups using the trial’s discharge criteria.[1]

Trial status and size

The trial status is Authorised.[1]

The planned enrollment is 300 people.[1]

Trial ID Phase Condition studied Status Enrollment
2025-525053-39-00 Phase 3 Coronary artery disease Authorised 300

Ongoing Clinical Trials on (2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID

  • A study to evaluate the effect of EA-230 on the hospital stay length for patients undergoing coronary artery bypass surgery for coronary artery disease.

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

Glossary

  • Coronary artery disease: A condition where the heart's blood vessels are narrowed or blocked.
  • On-pump coronary artery bypass grafting: Heart surgery that uses a heart-lung machine while new routes are made for blood to reach the heart.
  • Randomized: Patients are placed into study groups by chance.
  • Double-blind: Neither the patient nor the study team knows which treatment is being given.
  • Placebo: A look-alike treatment with no active study drug, used for comparison.
  • Phase 3: A later-stage trial that studies how well a treatment works and keeps watching safety.
  • Interventional study: A study where researchers give a treatment and then measure the results.
  • Enrollment: The number of people planned to join the study.
  • Primary outcome: The main result the researchers want to measure.
  • Length of stay: How long a patient stays in the hospital.
  • Median: The middle value in a set of numbers.

References

  1. https://clinicaltrials.gov/study/2025-525053-39-00